Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment-Reference-Cited by-同舟云学术

Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment

Published:2017-02 Issue:2 Volume:222 Page:363-371
ISSN:0171-2985
Container-title:Immunobiology
language:en
Short-container-title:Immunobiology

Author:

Subías Hidalgo Marta,Martin Merinero Hector,López Alicia,Anter Jaouad,García Sheila Pinto,Ataúlfo Gonzalez-Fernández Fernando,Forés Rafael,Lopez-Trascasa Margarita,Villegas Ana,Ojeda Emilio,Rodríguez de Córdoba Santiago^ORCID

Funder

Spanish “Ministerio de Economía y Competitividad”

Autonomous Region of Madrid

Publisher

Elsevier BV

Subject

Hematology,Immunology,Immunology and Allergy

Reference31 articles.

1. Paroxysmal Nocturnal Hemoglobinuria is rare cause for thrombosis of the intra-abdominal veins in the ethnic Indian population − results from FLAER-based flowcytometry screening;Ahluwalia;Eur. J. Haematol.,2014

2. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria;Brodsky;Blood,2008

3. Quantitative variations of the C3b/C4b receptor (CR1) in human erythrocytes are controlled by genes within the regulator of complement activation (RCA) gene cluster;de Cordoba;J. Exp. Med.,1986

4. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab;de Latour;Blood,2015

5. Reference Value Advisor: a new freeware set of macroinstructions to calculate reference intervals with microsoft excel;Geffre;Vet. Clin. Pathol.,2011

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploration of risk factors for hemoglobinuria and acute kidney injury following iliofemoral venous mechanical thrombectomy;Journal of Interventional Medicine;2023-02

2. Les inhibiteurs du complément : une vue d’ensemble;La Revue de Médecine Interne;2022-12

3. Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study;Journal of Blood Medicine;2022-08

4. Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria;Haematologica;2022-03-10

5. Safety of current treatments for paroxysmal nocturnal hemoglobinuria;Expert Opinion on Drug Safety;2020-12-15